Suboptimal consideration and management of potential familial hypercholesterolaemia in patients with suspected premature coronary artery disease

Singapore Medical Journal

Volumn 53, Issue 3, 2012, Pages 174-178

  Yudi, M ^a,b   Omera, L ^a   McCubbery, N ^a   Dick, S ^a   Jayasinghe, R ^a,b   Hamilton Craig, I ^b  

^a GOLD COAST UNIVERSITY HOSPITAL   (Australia)

^b GRIFFITH UNIVERSITY   (Australia)

Author keywords

Familial hypercholesterolaemia; LDL cholesterol; Premature coronary artery disease; Screening

Indexed keywords

ATORVASTATIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HEART INFARCTION; HUMAN; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; PREVALENCE; RECOMMENDED DRUG DOSE; RETROSPECTIVE STUDY; SCREENING;

ACUTE CORONARY SYNDROME; AGE DISTRIBUTION; AGE OF ONSET; ANGINA, UNSTABLE; BLOOD CHEMICAL ANALYSIS; CHEST PAIN; COHORT STUDIES; COMORBIDITY; CORONARY ARTERY DISEASE; EMERGENCY SERVICE, HOSPITAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIA TYPE II; INCIDENCE; MALE; MASS SCREENING; MIDDLE AGED; MYOCARDIAL INFARCTION; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEX DISTRIBUTION;

EID: 84858264853     PISSN: 00375675     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Marks D, Thorogood M, Neil HA, Humphries SE. A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis 2003; 168:1-14.
2. Williams RR, Hunt SC, Schumacher MC, et al. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. Am J Cardiol 1993; 72:171-176.
3. Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group. BMJ 1991; 303:893-896.
4. Familial hypercholesterolemia: report of a second WHO Consultation. In: World Health Organization: Geneva, Switzerland, 1999.
5. Leren TP. Cascade genetic screening for familial hypercholesterolemia. Clin Genet 2004; 66:483-487.
6. Neil HA, Hammond T, Huxley R, Matthews DR, Humphries SE. Extent of underdiagnosis of familial hypercholesterolaemia in routine practice: prospective registry study. BMJ 2000; 321:148.
7. Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Scientific Steering Committee on behalf of the Simon Broome Register Group. Atherosclerosis 1999; 142:105-112.
8. Neil A, Cooper J, Betteridge J, et al. Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. Eur Heart J 2008; 29:2625-2633.
9. Hamilton-Craig I, Kostner K, Colquhoun D, Woodhouse S. Ezetimibe in familial hypercholesterolaemia. Vascular Health Risk Manag 2010; 6:1023-1037.
10. Stone NJ, Levy RI, Fredrickson DS, Verter J. Coronary artery disease in 116 kindred with familial type II hyperlipoproteinemia. Circulation 1974; 49:476-488.
11. Slack J. Risks of ischaemic heart disease in familial hyperlipoproteinaemic states. Lancet 1969; 2:1380-1382.
12. Bates TR, Burnett JR, van Bockxmeer FM, et al. Detection of familial hypercholesterolaemia: a major treatment gap in preventative cardiology. Heart Lung Circ 2008; 17:411-413.
13. Hamilton-Craig I. Case-finding for familial hypercholesterolemia in the Asia-Pacific region. Semin Vasc Med 2004; 4:87-92.
14. Marks D, Thorogood M, Neil HA, Wonderling D, Humphries SE. Comparing costs and benefits over a 10 year period of strategies for familial hypercholesterolaemia screening. J Public Health Med 2003; 25:47-52.
15. Wonderling D, Umans-Eckenhausen MA, Marks D, et al. Cost-effectiveness analysis of the genetic screening program for familial hypercholesterolemia in The Netherlands. Semin Vasc Med 2004; 4:97-104.
16. Fahed AC, Safa RM, Haddad FF, et al. Homozygous familial hypercholesterolemia in Lebanon: a genotype/phenotype correlation. Mol Genet Metab 2011; 102:181-188.
17. Duff CJ, Hooper NM. PCSK9: an emerging target for treatment of hypercholesterolemia. Expert Opin Ther Targets 2011; 15:157-168.